Aim This post hoc analysis explored whether mealtime fast-acting insulin aspart treatment provided an advantage in postprandial plasma glucose (PPG) control vs. insulin aspart in people with Type 2 diabetes receiving high doses of bolus insulin.
Introduction
Excessive postprandial plasma glucose (PPG) excursions in people with Type 2 diabetes have been linked to increased mortality [1] , poor glycaemic control [2] and, consequentially, an increased risk of developing micro-and macrovascular complications [3] . People with insulin-resistant Type 2 diabetes receiving basal insulin and oral anti-diabetes drug therapy often require treatment intensification with bolus insulin to improve glycaemic control [4] . However, PPG control frequently remains suboptimal, even in people receiving a high bolus insulin dose [5, 6] . Further, conventional rapid-acting insulin analogues do not seem to offer a therapeutic advantage over regular human insulin in these people; this is concerning and highlights the need for more efficacious bolus insulins in this population.
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart containing niacinamide and Larginine, with an absorption profile that more closely approaches physiological early-phase insulin secretion than conventional rapid-acting insulin analogues. In people with Type 1 diabetes, mealtime faster aspart was shown to be non-inferior to mealtime insulin aspart in reducing HbA 1c [7, 8] . Further, faster aspart demonstrated superior PPG control with statistically significant improvements in both 1-h PPG [7, 8] and 2-h PPG increments [7] , compared with mealtime insulin aspart in people with Type 1 diabetes. In Type 2 diabetes, mealtime faster aspart was also demonstrated to be non-inferior to mealtime insulin aspart in terms of HbA 1c , with a statistically significant improvement in 1-h PPG increment in favour of faster aspart [9] . In both Type 1 and Type 2 diabetes, the overall rates of treatment-emergent hypoglycaemia and safety profiles were similar between the mealtime faster aspart and insulin aspart treatment arms [7] [8] [9] .
This post hoc analysis of the onset 2 trial (ClinicalTrials.-gov: NCT01819129) explored whether mealtime faster aspart provided advantages in PPG control over insulin aspart in people with Type 2 diabetes receiving different dose ranges of bolus insulin, including people on high doses.
Methods
This study was a post hoc, post-randomization, subgroup analysis of the onset 2 trial: a randomized, phase 3a, 26-week, double-blind, treat-to-target trial that compared mealtime faster aspart with mealtime insulin aspart, both in a basal-bolus regimen, in people with Type 2 diabetes uncontrolled on basal insulin therapy and metformin [9] .
After an 8-week run-in period to optimize basal insulin, participants were randomized (1:1) to mealtime faster aspart (n = 345) or insulin aspart (n = 344), titrated using a simple daily subject-driven algorithm, plus insulin glargine U100 and metformin. Faster aspart or insulin aspart was administered subcutaneously 0-2 min before a main meal. The effects of faster aspart and insulin aspart on PPG control were assessed using a standard liquid meal test (80 g carbohydrate) during the run-in period and after 26 weeks of randomized treatment. The bolus insulin dose used for the second meal test was individualized, calculated by dividing 80 by the product of 500 divided by the participant's total daily insulin dose. In the present post hoc analysis, participants were stratified into three post-randomization subgroups: meal test bolus insulin dose ≤ 10 units per dose (n = 171), > 10-20 units per dose (n = 289) or > 20 units per dose (n = 146), representing approximately 25%, 50% and 25% of the study population, respectively.
Statistical methods
All statistical analyses were based on the full analysis set. Estimated treatment difference for change from baseline in PPG increment (meal test) after 26 weeks of treatment was analysed by an analysis of variance (ANOVA) model, which included treatment by dose-group interaction, continuous glucose monitoring strata (a subgroup continuous glucose monitoring assessment was performed at selected sites at two periods during the trial) and region as factors, and the actual bolus dose and total daily dose (nested within dose group) at end of trial, as well as baseline PPG increment (meal test), as covariates. Because both basal and bolus insulin doses were included as covariates in the regression model, the treatment difference within each subgroup reflects the expected difference in PPG increment between a participant receiving faster aspart and a participant receiving insulin aspart who had the same basal and bolus insulin dose.
Results
In the overall onset 2 population, baseline characteristics were similar between those randomized to mealtime faster aspart and those randomized to mealtime insulin aspart [9] . For the current post hoc analysis, baseline characteristics across post-randomization subgroups (≤ 10, > 10-20 or > 20 units) were similar; the total daily actual basal insulin dose values were 40.7, 51.3 and 72.8 units for those in the ≤ 10, > 10-20 and > 20 units subgroups, respectively (Table 1) . Insulin dosing characteristics and body weight for all subgroups at week 26 are shown in the Appendix (Table A1 ). The mean age of the > 20 units bolus insulin dose subgroup was 58 years; mean BMI was 33.1 kg/ m 2 ; mean duration of diabetes was~12 years; and the mean meal test bolus insulin dose at week 26 was 33.4 units. In the > 20 units bolus insulin dose subgroup, a statistically significant treatment difference in favour of faster aspart vs. insulin aspart was observed for the change from baseline in PPG increment at all post-meal time points from 1-4 h (Fig. 1 ). There were no other significant treatment differences in favour of faster aspart in the ≤ 10 and > 10-20 units dose subgroups at any post-meal time point from 1-4 h (Fig. 1 ).
There were no statistically significant differences in the magnitude of change from baseline in HbA 1c and 1,5-anhydroglucitol levels at week 26 between faster aspart and insulin aspart in any of the bolus insulin dose subgroups (Table A2) .
Discussion
This post hoc analysis explored whether mealtime faster aspart provides better PPG control than conventional insulin aspart in people with Type 2 diabetes according to their degree of insulin resistance as reflected in their titrated doses of bolus insulin.
Overall, in the onset 2 trial, mealtime faster aspart significantly improved PPG control at the 1-h time point only, compared with mealtime insulin aspart [estimated Faster aspart, fast-acting insulin aspart. insulin (both faster aspart and insulin aspart) had a mean body weight of 100.1 kg and were receiving, on average, 128.5 and 206.3 units of total daily bolus insulin and total daily insulin, respectively, at 26 weeks (Table A1 ). There was, however, no difference in the magnitude of change in HbA 1c or 1,5-anhydroglucitol levels between faster aspart and insulin aspart, in this or any other subgroup after 26 weeks of treatment, a finding consistent with the primary analysis. A plausible reason why the PPG advantage of faster aspart in the high-dose group may not translate into an advantage in HbA 1c or 1,5-anhydroglucitol levels could be that a mealtime bolus dose calibration (up to 1-unit dose increase or decrease) in this trial was based on the prior day's total daily insulin usage rather than a value that is prospectively computed from the actual carbohydrate content of a meal about to be consumed and the carbohydrate-insulin ratio estimate (e.g. one derived from '500' formula). It should be noted that the post hoc analysis did not explore the rates of overall or meal-related hypoglycaemia with faster aspart vs. insulin aspart by bolus insulin subgroup. The PPG advantage of faster aspart may have been most evident in those receiving > 20 units of bolus insulin because these people had a higher observed BMI than those receiving lower doses. The absorption of rapid-acting insulin analogues is delayed in people with obesity, and the glucoselowering action is further delayed as the dose of the insulin is increased [5] . This effect has been attributed to reduced subcutaneous blood flow associated with increased adiposity [10] . It is possible that the formulation of faster aspart overcomes, to some degree, the barrier to early absorption in more insulin-resistant people with obesity, particularly when delivered as a larger dose (with a proportional delivery of a larger dose of niacinamide) within the subcutaneous depot. With greater early insulin absorption and action, a significant impact on postprandial control would be anticipated [11] [12] [13] . The improvement in PPG control observed with faster aspart compared with insulin aspart might also be brought about by greater early suppression of endogenous glucose production [14] . Although these results are intriguing, analyses of subgroups defined post randomization are susceptible to inherent bias, and causality assessments should be interpreted cautiously. With this caveat, this post hoc analysis of the onset 2 study [9] suggests that improvements in PPG control in Type 2 diabetes with faster aspart were more pronounced in those receiving the highest bolus insulin doses, indicating that faster aspart holds promise as a more effective treatment than insulin aspart for controlling PPG in people with insulin-resistant Type 2 diabetes. However, this potential benefit requires further confirmation in clinical practice.
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